Skip to Main Content

In the early stages of the race to develop Covid-19 vaccines, it wasn’t clear how many would work, which manufacturers would score successes, or which projects would fall by the wayside.

Now, just a few days past the first anniversary of the start of Moderna’s Phase 1 trial — the first to begin in the United States — we have a much clearer picture of the Covid vaccine landscape.


Indeed, the focus is now sharp enough to start to call out some early winners and early losers. The fate of some development work remains uncertain, but one thing can be stated with conviction — the world already has a number of highly protective Covid vaccines and may have several more, both in first-generation iterations and in next-generation products aimed at troublesome variants.  

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!